An interventional study of Neurocardiac rehabilitation program and Standard of care in Congenital Heart Disease, sponsored by University Hospital, Bordeaux. Recruiting at 6 sites in 3 countries. Open to participants aged 8 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.
Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 11th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2024, is one of 27 with no phase, reaches primary completion later than 16 of the 21 other live ones, and was the 54th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 0–18
Nantes University Hospital · Sites in France
Ages 0 min–36 mo
Nantes University Hospital · Sites in France
Ages up to 6 mo
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 50
University Hospital, Bordeaux · Sites in France
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 8 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 91 across the 34 interventional studies, 300 across the 39 observational. Of the 39 that completed or were terminated, 5 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 73 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 7 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Defects, Congenital with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
| NCT07864129University Hospital, Strasbourg, FranceVolution of Pulmonary Artery Dimensions in Tetralogy of Fallot | 2027-04-18 |
| NCT06998290University Hospital, BordeauxFeasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life | 2027-06-01 |
| NCT06442592Nantes University HospitalCharacterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects | 2027-07-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 73 studies in Heart Defects, Congenital with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Remarkable progress in paediatric cardiology and surgery have led to the substantial increase of congenital heart disease (CHD) survivors. Long-term outcomes in rare and complex CHD have become a critical priority as three major sources of morbidity have been identified in this population: neurodevelopmental sequelae, mental health issues and reduced exercise capacity. These challenges adversely affect their quality of life and constitute a major public health issue. We seek to evaluate the efficacy of the first integrative and holistic program in Neuro-Cardiac Health associating physical and psychological rehabilitation for children with rare CHD compared to the standard of care. Children randomly assigned to the intervention will undergo a 12-week neuro-cardiac intervention including home-based adaptive physical exercise, telehealth parent and child psycho-education and child computerized cognitive training, as well in-person individual sessions of intervention reinforcement. Parents will be actively involved and will receive personalized feedback and educational resources. Children assigned to the control group will receive the standard of care in congenital cardiology. Post-intervention effects will be measured after 12-months on several outcomes including health-related quality of life (HRQoL), trained and untrained cognitive skills, mental health outcomes and cardiovascular/physical variables.
Neurodevelopmental and mental health issues and reduced exercise capacity are the most frequent long-term morbidities in youth with CHD. These problems worsen with age and play a critical role in reducing the quality of life of patients and their families. The QUALI-NEUROREHAB CHD multicentre, randomized controlled trial seeks to test the efficacy of an innovative home-based neuro-cardiac intervention to improve physical and mental health of children, adolescents and young adults with rare CHD, as assessed by the patients themselves using patient-reported outcomes and standardized assessments. Outcomes relate to changes in scores for health-related quality of life (HRQoL, primary outcome measure), neurodevelopmental and mental health outcomes, and cardiopulmonary exercise test parameters, 12 months post-enrolment, in patients with rare CHD aged 8 to 25 years old. This is a two-arm parallel design study: intervention versus control. Intervention using the neuro-cardiac rehabilitation program will be the active arm. Standard of care will be used for the control group and involves normal cardiology consultations and follow-up without intervention programs on physical activity or neurocognitive training. The intervention group will include 12 weeks of neuro-cardiac training, comprised of at-home adaptive physical exercise, telehealth consultations and computerized neurocognitive training as well in-person individual sessions of intervention reinforcement. We hypothesize an increase in the overall HRQoL score of 6 ± 14 points (over 100). With a 80% power, a bilateral alpha risk of 5%, and potentially 10% of loss to follow-up and/or missing data on the primary outcome, we need to randomize 96 patients to each group (N= 192, overall). Analysis will be performed using intent to treat (ITT) approach. We predict significant positive changes in quality of life, mental and physical health scores in patients who will be assigned to the neuro-cardiac intervention (active arm). If this intervention is effective, it can have critical public health implications for the organization and modalities of care for children with rare CHD in Europe. A neuro-cardiac rehabilitation programme tailored to the specific challenges of individuals with rare CHD would improve patient care pathways across major centers in Europe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The home-based neuro-cardiac rehabilitation program will consist of weekly sessions of neuro-cardiac training during 12 weeks at home. * The physical activity training consists of two 1-hour sessions of adapted physical activities per week supervised by an APA educator or equal. One weekly session is held in person, at home, and the second one in videoconference. All training sessions follow the same scheme with 30 minutes of bicycle training, adapted from high-intensity training (30-33), and 30 minutes of "free" adapted physical activities * The neuropsychological component will consist of 2 home-based weekly 25-minute sessions of computerized cognitive training via the new platform of CogMed (standard format) for the patient and 1 weekly 30/45-min teleconsultation session of neuropsychological feedback on every-day life emotional regulation and executive functioning applied to school and family life for either the parent (for ages 17 and younger) or young adults with CHD.
Other: Neurocardiac rehabilitation program
The control group will follow European recommendations for cardiology care (standard of care) without introducing any additional interventions for research purposes at the exception of primary (HRQoL questionnaires) and secondary outcomes
Other: Standard of care
Patients receiving a neurocardiac rehabilitation program for 12 weeks.
No intervention during the neurocardiac rehabilitation program
Total score of the Pediatric Quality of Life Inventory (PedsQL) 4.0 questionnaire
Change in the self-reported total score of the PedsQL 4.0 questionnaire between baseline (Month 0) and the end of follow-up (Month 12) in both groups.
Time frame: between Month 0 and Month 12
Proxy-reported total score of the Pediatric Quality of Life Inventory (PedsQL) for paediatric patients
Time frame: between Month 0 and Month 12
Pediatric Quality of Life Inventory (PedsQL) 4.0 Health-related quality (HRQoL ) of life questionnaire score per dimension (self and proxy reports)
Time frame: between Month 0 and Month 12
Behaviour Rating Inventory of Executive Function (BRIEF) scale scores
BRIEF (8-18 years) and BRIEF-A (older than 18 years) These scales make it possible to identify executive dysfunctions that have an impact on daily life. BRIEF assesses behaviours based on questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and control. For the BRIEF-A (18 years and +), 9 scales are available and those yield the same indices and general composite score.
Time frame: between Month 0 and Month 12
Wisconsin Card Sorting Test scale score
This test measures higher-order executive functioning including planning, anticipation, and cognitive flexibility.
Time frame: between Month 0 and Month 12
Wechsler Intelligence Scale scores
Scores on the main indices of the Wechsler Intelligence Scale (WISC-V for children, WAIS-IV for adults): verbal comprehension, visual-spatial abilities, working memory, fluid reasoning and processing speed.
Time frame: between Month 0 and Month 12
NEPSY-II scale scores
Score on tests of language (comprehension of instructions) and social cognition (understanding of facial emotions and theories of mind) from the NEPSY-II Child Neuropsychological Assessment battery
Time frame: between Month 0 and Month 12
Wechsler Adult Memory Scale scores
verbal and visual memory tests
Time frame: between Month 0 and Month 12
Vineland questionnaire
The Vineland-2 proxy-questionnaire of adaptive functioning: this is a parent- or other informant report on adaptive skills including social, communication, academic and daily-life independence of children.
Time frame: between Month 0 and Month 12
Multiscore Depression Inventory for Children (MDI-C) scale score
Scale providing access to the child's emotional world and more specifically to depression through 8 dimensions: self-esteem, anxiety, sad mood, social introversion, pessimism, defiance, low energy, and feelings of powerlessness.
Time frame: between Month 0 and Month 12
Beck's Depression Inventory (BDI) scale score
Self-report questionnaire (BDI-2) used to measure the characteristic attitudes and symptoms of depression
Time frame: between Month 0 and Month 12
Revised Child Manifest Anxiety Scale (R-CMAS) score
Self-administered questionnaire providing a more specific assessment of anxiety in its multiple expressions: worry/hypersensitivity, physiological anxiety, and social concern/concentration, based on a global measure of the child's or adolescent's anxiety level.
Time frame: between Month 0 and Month 12
State-Trait Anxiety Inventory (STAI) - Form Y score
Time frame: between Month 0 and Month 12
Resilience Scale score
Resilience Scale for Children (RS10) score and Resilience Scale for Adults: self-administered questionnaire relating to the ability to cope and respond to life events.
Time frame: between Month 0 and Month 12
Cardiopulmonary exercise test (CPET)
Time frame: between Month 0 and Month 12
Muscular strength
Muscular strength measured using a handgrip dynamometer . This parameter represents the strength of the upper extremities and correlates with inspiratory muscle function and Vital Capacity (FVC) of the lungs. It is measured three times on both hands while sitting with the elbows in a rectangular position. The highest value of the better arm will be used.
Time frame: between Month 0 and Month 12
Metabolic equivalent of task (MET)
Physical activity intensity and energy expenditure measured by an actimeter
Time frame: between Month 0 and Month 12
Following physical activity questionnaires
Self-administrated questionnaire : International Physical Activity Questionnaire(IPAQ) for patients ≥18 years
Time frame: between Month 0 and Month 12
Following physical activity questionnaires
Self-administrated questionnaire : Physical Activity Questionnaire for Children (PAQ-C) for 14 to 17-year-old children
Time frame: between Month 0 and Month 12
Following physical activity questionnaires
Self-administrated questionnaire : Physical Activity Questionnaire for Children (PAQ-A) for 8 to 14-year-old children
Time frame: between Month 0 and Month 12
Plan to share: Yes — Access to participants' personal data will be subject to compliance with applicable laws and regulations, the information provided to participants, and the provisions on confidentiality and publication set out in the project's consortium agreement
Started Jun 2024 (actual). Primary completion is estimated for Jun 2028, 48 months after the start.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 48 months is above that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →